I last covered Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT ) in May 2024, rating the stock as a Hold based on the company’s reliance on Zoryve. I was skeptical about the company’s capacity to translate theirOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatme ...